oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Oncgnostics expands international distribution
Press ReleasesJena, July 22 – Oncgnostics GmbH signs an agreement with Seegene Germany GmbH for the international distribution of its own tests. Dr. Alfred Hansel, Managing Director of Oncgnostics: “The agreement […]
Psychological stress in cervical cancer tabood
Press ReleasesMedia study: A recent media study by Oncgnostics GmbH shows that, although the general media report on the topic of cervical cancer, they do not address the associated psychological stress […]
Molecular biological cancer diagnostics close gaps in cancer screening
Press ReleasesTwo tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test […]
Hong Kong firm invests in Jena-based Oncgnostics GmbH
Press ReleasesJena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer […]
Cancer diagnostics of the future thanks to highly informative biomarkers
Press Releasesoncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At […]
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Press ReleasesGynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. […]
PCR test detects cervical precancerous lesions
Blog, Press ReleasesJena, Germany, May 25th 2022 – May 28 marks the 35th International Day of Action for Women’s Health. One “female” disease that should no longer exist due to the availability […]
Cancer prevention remains a matter of the heart: Biotech company oncgnostics celebrates 10th anniversary
Press ReleasesThe company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in […]
Pilot study: Cancer screening from home is possible
Press ReleasesA large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much […]
Study „OroCa-Graz“ – Study on Head-and-Neck tumors: oncgnostics GmbH cooperates with the Medical University of Graz
Press ReleasesThe biotechnology company oncgnostics GmbH is researching a method for diagnosing Head-and-Neck tumors together with the clinical department for general ENT at the Medical University of Graz as part of […]